Iridex receives FDA clearance for Cyclo G6 Laser System | Ophthalmology

The U.S. Food and Drug Administration issued 510(k) clearance for the Cyclo G6 Laser System to treat glaucoma, according to a press release from Iridex.

 

“The Cyclo G6 system extends the reach of Iridex’s proprietary MicroPulse technology to a broader group of ophthalmologists who are seeking better alternatives for treating glaucoma than drug regimens or invasive surgical procedures,”

 

The system will be sold with two disposable delivery probes, the MicroPulse P3 and the G-Probe. Iridex intends to add new probes later this year for a broader range of treatment applications, the release said.

 

Home for surgical videos and meeting presentations, along with “Video Perspectives” from key opinion leaders who provide insight on current news and information relevant to your practice.

 

From the podium to practice. Ocular Surgery News’ award-winning journalists and editors produce live editorial and video coverage from the most important clinical meetings in ophthalmology.

 

You can find out “What your colleagues are saying today” by reading Healio’s award-winning MedBlog. MedBlog is the home of more than 40 physician and professional blogs in nine medical specialties.

 

Curated from Iridex receives FDA clearance for Cyclo G6 Laser System | Ophthalmology